MONTREAL, QUEBEC--(Marketwire - November 17, 2009) - Bio-Solutions Corp. (OTCBB: BISU), announces a mission to perform a pilot trial for its main product GreenEx™ in a highly infested site within one of the targeted countries.
In its growth framework and discussion with three African Countries, Bio-Solutions Corp. accomplishes a second and important step, i.e. a first pilot trial design to show on site efficiency of GreenEx™ in December, 2009. "We are proud to have the opportunity to show the effectiveness of our product so quickly after its regulatory approval by the health authorities of this West African country. Bio-Solutions Corp's Team will travel to the West African Country to evaluate the environmental condition in order to develop the perfect spreading strategy to assure the success of this experiment. This will be the final step prior to a commercial supply agreement," declares Dr Chaumillon.
Bio-Solutions Corp commercial strategy and turnkey operation approach seems to be the answer to the field problematic of the malaria infested countries. "In less than 6 months we have registered our product with the regulatory and conformity authorities. Now we are offered the possibility to demonstrate the efficiency of the GreenEx™ product directly under scrutiny of ministry of health experts." stressed Dr Chaumillon. Trial design and experiment will be completed in the next 60 days before starting the last phase; i.e. supply agreement negotiation.
For more information on Bio-Solutions Corp. and its products, please visit the company's website at www.bio-solutionscorp.com
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of studies, the ability of the Company to take advantage of business opportunities in the biotechnology industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.